Xuebijing injection reduces COVID-19 patients' mortality as influenced by the neutrophil to lymphocyte platelet ratio.
10.1016/j.joim.2025.04.002
- Author:
Man LIAO
1
;
Li-Ting ZHANG
1
;
Li-Juan BAI
1
;
Rui-Yun WANG
1
;
Yun LIU
1
;
Jing HAN
1
;
Li-Hua LIU
2
,
3
;
Ben-Ling QI
3
,
4
Author Information
1. Department of General Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
2. Department of General Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China. Electronic address: huahuahbhb@
3. com.
4. Department of General Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China. Electronic address: qibenlingok_2015@
- Publication Type:Journal Article
- Keywords:
COVID-19;
Inflammatory markers;
Neutrophil to lymphocyte platelet ratio;
Traditional Chinese medicine;
Xuebijing injection
- MeSH:
Humans;
Drugs, Chinese Herbal/administration & dosage*;
Male;
Female;
Retrospective Studies;
Aged;
Neutrophils;
COVID-19 Drug Treatment;
COVID-19/blood*;
Middle Aged;
Prognosis;
Lymphocytes;
Blood Platelets;
Platelet Count;
SARS-CoV-2;
Aged, 80 and over;
Adult
- From:
Journal of Integrative Medicine
2025;23(3):282-288
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:Xuebijing injection has been recommended as a therapeutic approach for individuals with severe and critical COVID-19. This study aims to explore the correlation of neutrophil to lymphocyte platelet ratio (NLPR) with the severity and prognosis of COVID-19, and the effect of XBJ on the prognosis of patients with COVID-19 in different inflammatory states.
METHODS:This was a retrospective study conducted at Wuhan Union Hospital in China. COVID-19 patients admitted between November 1, 2022 and February 1, 2023 were included. In predicting prognosis for individuals with COVID-19, new inflammatory indicators were used, and their prognostic value was assessed by using Cox regression models and receiver operating characteristic curves. Furthermore, a calculation was made to determine the cutoff value for NLPR. Relative risk and Cox regression models were used to examine the effects of Xuebijing injection on prognosis in patient cohorts that had been stratified by the NLPR cutoff.
RESULTS:This research included 455 participants with COVID-19, with a mean age of 72 years. Several inflammatory indicators were found to be strongly correlated with prognosis, and NLPR shows the greatest predictive power. Patients with NLPR > 3.29 exhibited a mortality rate of 17.3%, which was 6.2 times higher than in patients with NLPR ≤ 3.29. Importantly, providing Xuebijing injection to patients with NLPR > 3.29 was associated with a lower risk of 60-day all-cause mortality. However, there was no discernible improvement in survival among patients with NLPR ≤ 3.29 who received Xuebijing injection.
CONCLUSION:NLPR is the most reliable inflammatory marker for predicting prognosis among individuals with COVID-19, and can accurately identify individuals who may benefit from Xuebijing injection. Please cite this article as: Liao M, Zhang LT, Bai LJ, Wang RY, Liu Y, Han J, Liu LH, Qi BL. Xuebijing injection reduces COVID-19 patients mortality as influenced by the neutrophil to lymphocyte platelet ratio. J Integr Med. 2025; 23(3): 282-288.
